Skip to main content

Table 1 Clinical, biological and densitometry data at baseline

From: A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab

Parameter Whole population Infliximab (n = 90) No infliximab (n = 99) P
Age 52.5 ± 14.2 50.9 ± 11.8 53.9 ± 15.9 NS
Women (n [%]) 152 (80) 74 (82) 78 (79) NS
Disease duration (years) 10.6 ± 9.0 10.2 ± 9.1 10.9 ± 8.9 NS
Patients on steroids (n [%]) 118 (62) 56 (62) 62 (63) NS
Mean dose steroids (mg/day) 5.30 ± 5.79 5.40 ± 5.75 5.26 ± 5.83 NS
DAS28 score 5.17 ± 1.07 5.37 ± 0.94 5.00 ± 1.15 NS
Patients on biphosphonates (n [%]) 35 (19) 15 (17) 20 (20) NS
Calcaemia (mmol/l) 2.28 ± 0.13 2.32 ± 0.12 2.24 ± 0.12 NS
Alkaline phosphatase (U/l) 74.6 ± 25.6 77.5 ± 29.5 72.0 ± 21.2 NS
Osteocalcin (ng/ml) 19.9 ± 11.8 18.4 ± 9.7 21.2 ± 13.4 NS
CTX-I (pg/ml) 446 ± 307 482 ± 386 418 ± 227 NS
Parathyroid hormone (pg/ml) 30.5 ± 17.6 28.7 ± 15.4 32.0 ± 19.1 NS
25-hydroxycholecalciferol (ng/ml) 19.7 ± 10.3 18.2 ± 10.1 21.2 ± 10.4 NS
Femoral neck BMD (g/cm2) 0.801 ± 0.159 0.807 ± 0.156 0.797 ± 0.162 NS
Lumbar BMD (g/cm2) 0.911 ± 0.143 0.930 ± 0.142 0.896 ± 0.142 NS
Patients with neck osteopenia (n [%]) 96 (51) 47 (52) 49 (50) NS
Patients with lumbar osteopenia (n [%]) 93 (49) 40 (45) 53 (54) NS
Patients with neck osteoporosis (n [%]) 37 (20) 18 (20) 19 (19) NS
Patients with lumbar osteoporosis (n [%]) 37 (19) 15 (17) 23 (23) NS
  1. Values are shown for each parameter at baseline, expressed as mean ± standard deviation or n (%). Data for both groups (case and control) were compared using the unpaired Student's t-test for continuous variables and the χ2 test for discrete variables. BMD, bone mineral density; CTX-I, C-terminal cross-linking telopeptide of type I collagen; DAS, Disease Activity Score; NS, not signficant.